Cited by 201Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

The X11α protein slows cellular amyloid precursor protein processing and reduces Aβ40 and Aβ42 secretion

Open access
Borg, Jean-Paul, Yang, Yunning, De Taddéo-Borg, Mylène, Margolis, Ben, Turner, R. Scott·1998·Journal of Biological Chemistry

Abstract

Constitutive amyloid precursor protein (APP) metabolism results in the generation of soluble APP (APPs) and Abeta peptides, including Abeta40 and Abeta42-the major component of amyloid plaques in Alzheimer's disease brain. The phosphotyrosine binding (PTB) domain of X11 binds to a peptide containing a YENPTY motif found in the carboxyl terminus of APP. We have cloned the full-length X11 gene now referred to as X11alpha. Coexpression of X11alpha with APP results in comparatively greater levels of cellular APP and less APPs, Abeta40, and Abeta42 recovered in conditioned medium of transiently transfected HEK 293 cells. These effects are impaired by a single missense mutation of either APP (Y682G within the YENPTY motif) or X11alpha (F608V within the PTB domain), which diminishes their interaction, thus demonstrating specificity. The inhibitory effect of X11alpha on Abeta40 and Abeta42 secretion is amplified by coexpression with the Swedish mutation of APP (K595N/M596L), which promotes its amyloidogenic processing. Pulse-chase analysis demonstrates that X11alpha prolongs the half-life of APP from approximately 2 h to approximately 4 h. The effects of X11alpha on cellular APP and APPs recovery were confirmed in a 293 cell line stably transfected with APP. The specific binding of the PTB domain of X11alpha to the YENPTY motif-containing peptide of APP appears to slow cellular APP processing and thus reduces recovery of its soluble fragments APPs, Abeta40, and Abeta42 in conditioned medium of transfected HEK 293 cells. X11alpha may be involved in APP trafficking and metabolism in neurons and thus may be implicated in amyloidogenesis in normal aging and Alzheimer's disease brain.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1074/jbc.273.24.14761

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The half-life of APP695 in control HEK 293 cells is 2.6 h.

    “The half life of APP695 in control 293 cells was 2.6 h, a value that is consistent with prior studies (Borg et al., 1998).”

    From LRAD3, A Novel Low-Density Lipoprotein Receptor Family Member That Modulates Amyloid Precursor Protein Trafficking (2011) · cites this paper as Borg et al., 1998

    The X11α Coexpression section reports an APP half-life of approximately 2 hours in HEK 293 cells, and the Experimental Procedures specify that the study used APP695. This supports a similar control-cell half-life, but the source does not report the cited value of 2.6 hours. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • APP and ApoER2 bind the adaptor proteins X11α/β, Fe65, Snx17, Dab1, and Dab2, and these interactions regulate their surface expression and processing.

    “Intracellularly, APP and ApoER2 bind the adaptor proteins X11␣/␤ (67-70), Fe65 (69, 71, 72), Snx17 (73, 74), Dab1 (75-79), and Dab2 (73, 80), and these interactions regulate their surface expression and processing (Fig. 4).”
  • Surface localization of APP and ApoER2 and non-amyloidogenic processing of APP are altered by intracellular interactions with X11α/β.

    “X11␣/␤ (right panel) (67-70).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 8

  1. Hardy, J. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 2095-2097
  2. Guenette, S. Y., Chen, J., Jondro, P. D., and Tanzi, R. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 10832-10837
  3. Xu, H., Sweeney, D., Wang, R., Thinakaran, G., Lo, A. C. Y., Sisodia, S., Greengard, P., and Gandy, S. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 3748 -3752
  4. Busciglio, J., Gabuzda, D. H., Matsudaira, P., and Yankner, B. A. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 2092-2096
  5. Wertkin, A. M., Turner, R. S., Pleasure, S. J., Golde, T. E., Younkin, S. G., Trojanowski, J. Q., and Lee, V. M.-Y. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 9513-9517
  6. Tienari, P. J., Ida, N., Ikonen, E., Simons, M., Weidemann, A., Multhaup, G., Masters, C. L., Dotti, C. G., and Beyreuther, K. (1997) Proc. Natl. Acad. Sci.
  7. Cook, D. G., Sung, J. C., Golde, T. E., Felsenstein, K. M., Wojczyk, B. S., Tanzi, R. E., Trojanowski, J. Q., Lee, V. M.-Y., and Doms, R. W. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 9223-9228
  8. Sturchler-Pierrat, C., Abramowski, D., Duke, M., Wiederholt, K.-H., Mistl, C., Rothacher, S., Lederman, B., Burki, K., Frey, P., Paganetti, P. A., Waridel, C., Calhoun, M. E., Jucker, M., Probst, A., Staufenbiel, M., and Sommer, B. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 13287-13292

Cited by

Sorted by citations

Authors
Borg, J.-P., Yang, Y., De Taddéo-Borg, M., Margolis, B., & Turner, R. S.
Affiliations
  • Howard Hughes Medical Institute (US)
  • University of Michigan (US)
Corresponding author
Turner, R. Scott
Venue
Journal of Biological Chemistry
Publisher
Elsevier BV
Published
1998-06
Volume
273
Issue
24
Pages
14761-14766
ISSN
0021-9258 (ISSN-L)
OpenAlex
W1994346902
Cited by
201
References
40
Citations by year
2026: 1 · 2025: 2 · 2024: 3 · 2023: 2 · 2022: 1 · 2021: 2 · 2019: 4 · 2018: 1 · 2017: 3 · 2016: 3 · 2015: 1 · 2014: 4 · 2013: 4 · 2012: 10
FWCI
10.04
Type
journal article
Language
en
Open access
Locations
  • Journal of Biological Chemistry (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health
  • National Institute on Aging (P50AG008671, P50 AG08671)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
amyloid precursor protein, APP processing, amyloid-beta secretion, Aβ40, amyloid-beta 42, phosphotyrosine binding domain, APP trafficking, Swedish mutation, Alzheimer's disease, amyloidogenesis, soluble APP
MeSH terms
Alzheimer Disease, Binding Sites, Cell Line, Cloning, Molecular, Humans, Kidney, Molecular Sequence Data, Mutation, Nerve Tissue Proteins, Endopeptidases, Protein Processing, Post-Translational, Gene Expression, Amyloid beta-Peptides, Aspartic Acid Endopeptidases, Amyloid beta-Protein Precursor, Culture Media, Conditioned, Sequence Analysis, DNA, Phosphotyrosine, Amyloid Precursor Protein Secretases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review